Degarelix
- TRADE NAME: Firmagon (Ferring)
- INDICATIONS: Advanced hormone-dependent prostate cancer
- CLASS: Gonadotropin-releasing hormone (GnRH) antagonist
- HALF-LIFE: 43 days
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alfuzosin, Amiodarone, Antipsychotics, Artemether/Lumefantrine, Chloroquine, Ciprofloxacin, Cisapride, Disopyramide, Dofetilide, Dronedarone, Gadobutrol, Ibutilide, Moxifloxacin, Nilotinib, Pimozide, QT prolonging agents, Quinidine, Quinine, Sotalol, Tetrabenazine, Thioridazine, Ziprasidone
PREGNANCY CATEGORY: X
Please login to see the rest of this drug profile
SKIN.
HAIR.
NAILS.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OTIC.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric